Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy.
Rwibasira Rudinga, Gamariel; Khan, Ghulam Jilany; Kong, Yi.
Int J Mol Sci
; 19(2)2018 Feb 14.
Artigo em Inglês | MEDLINE | ID: mdl-29443899
Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles.
Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking.
Agents antiplaquettaires et athérothrombose.
Sustained increase in platelet aggregation after the cessation of clopidogrel.
Protease-activated receptor-1 antagonists: focus on SCH 530348.
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
Discovery of a vorapaxar analog with increased aqueous solubility.
PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.
Protease receptor antagonism to target blood platelet therapies.